[go: up one dir, main page]

PE20110075A1 - Sintesis de compuestos de ester borico - Google Patents

Sintesis de compuestos de ester borico

Info

Publication number
PE20110075A1
PE20110075A1 PE2009001314A PE2009001314A PE20110075A1 PE 20110075 A1 PE20110075 A1 PE 20110075A1 PE 2009001314 A PE2009001314 A PE 2009001314A PE 2009001314 A PE2009001314 A PE 2009001314A PE 20110075 A1 PE20110075 A1 PE 20110075A1
Authority
PE
Peru
Prior art keywords
halogen
aliphatic
ether
terc
aryl
Prior art date
Application number
PE2009001314A
Other languages
English (en)
Inventor
I Fraser Pickersgill
John Bishop
Christoph Koellner
Jean-Marc Gomez
Achim Geiser
Robert Hett
Vince Ammoscato
Stephen Munk
Young Lo
Fang-Ting Chiu
Vithalanand R Kulkarni
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34968044&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20110075(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of PE20110075A1 publication Critical patent/PE20110075A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/04—Esters of boric acids
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Catalysts (AREA)

Abstract

SE REFIERE A UN PROCESO DE PREPARACION DE UN COMPUESTO DE ESTER BORICO DE FORMULA (I) DONDE R1 ES UN GRUPO ALIFATICO C1-C8, ARILO C6-C10 O (ARILO C6-C10)-(ALIFATICO C1-C6); R2 ES H, HALOGENO; R3 ES HALOGENO; R4 Y R5 SON CA UNO ALIFATICO C1-C12, AROMATICO C6-C14, HETEOAROMATICO DE 5 A 14 MIEMBROS CON 1-4 HETEROATOMOS SELECCIONADOS DE O, N, S. DICHO PROCESO COMPRENDE LAS ETAPAS DE: A) PROPORCIONAR UN COMPLEJO BORON"ATO" DE FORMULA (II) DONDE Y ES HALOGENO, M+ ES Li+, Na+, K+; R1 A R5 ES COMO SE HA DEFINIDO ANTERIORMENTE; B) PONER EN CONTACTO EL COMPLEJO CON UN ACIDO LEWIS TALES COMO CLORURO DE ZINC, CLORURO FERRICO, BROMURO DE ZINC, ENTRE OTROS. DICHA ETAPA SE REALIZA MEDIANTE UNA MEZCLA QUE COMPRENDE UN DISOLVENTE ETER SELECCIONADO DE TERC-BUTIL METIL ETER, TERC-BUTIL ETIL ETER, ISOPROPIL ETER, ENTRE OTROS Y UN COSOLVENTE DE COORDINACION SELECCIONADO DE DIOXANO, AGUA, DIOXANO, TETRAHIDROFURANO Y MEZCLAS DE LOS MISMOS; C) LAVAR LA MEZCLA DE REACCION CON UNA SOLUCION ACUOSA; D) CONCENTRAR LA MEZCLA DE REACCION
PE2009001314A 2004-03-30 2005-03-29 Sintesis de compuestos de ester borico PE20110075A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US55753504P 2004-03-30 2004-03-30

Publications (1)

Publication Number Publication Date
PE20110075A1 true PE20110075A1 (es) 2011-02-17

Family

ID=34968044

Family Applications (3)

Application Number Title Priority Date Filing Date
PE2009001314A PE20110075A1 (es) 2004-03-30 2005-03-29 Sintesis de compuestos de ester borico
PE2014001477A PE20142402A1 (es) 2004-03-30 2005-03-29 Sintesis de compuestos de ester y acido borico
PE2005000359A PE20060162A1 (es) 2004-03-30 2005-03-29 Sintesis de compuestos de ester y acido borico

Family Applications After (2)

Application Number Title Priority Date Filing Date
PE2014001477A PE20142402A1 (es) 2004-03-30 2005-03-29 Sintesis de compuestos de ester y acido borico
PE2005000359A PE20060162A1 (es) 2004-03-30 2005-03-29 Sintesis de compuestos de ester y acido borico

Country Status (41)

Country Link
US (14) US7714159B2 (es)
EP (5) EP1756121B1 (es)
JP (4) JP4558039B2 (es)
KR (1) KR100939598B1 (es)
CN (5) CN108329337B (es)
AR (3) AR049374A1 (es)
AT (1) ATE521612T1 (es)
AU (1) AU2005230930B2 (es)
BR (1) BRPI0509587A (es)
CA (4) CA2738706C (es)
CL (2) CL2010000350A1 (es)
CR (1) CR8653A (es)
CY (3) CY1112053T1 (es)
DK (4) DK2377869T3 (es)
DO (1) DOP2011000293A (es)
EA (1) EA012927B1 (es)
EC (1) ECSP066960A (es)
ES (4) ES2457593T3 (es)
FI (1) FI4008721T3 (es)
HK (4) HK1100004A1 (es)
HR (4) HRP20212002T1 (es)
HU (2) HUE065769T2 (es)
IL (3) IL178250A (es)
LT (2) LT4008721T (es)
ME (1) ME01975B (es)
MX (1) MX367324B (es)
MY (1) MY145427A (es)
NL (3) NL1028639C2 (es)
NO (4) NO338905B1 (es)
NZ (3) NZ598172A (es)
PE (3) PE20110075A1 (es)
PL (4) PL1756121T3 (es)
PT (4) PT4008721T (es)
RS (4) RS65253B1 (es)
SG (5) SG10201800972PA (es)
SI (4) SI2377869T1 (es)
TW (1) TWI386212B (es)
UA (1) UA90108C2 (es)
UY (3) UY28830A1 (es)
WO (1) WO2005097809A2 (es)
ZA (1) ZA200608689B (es)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083903A (en) * 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
SG10201800972PA (en) 2004-03-30 2018-03-28 Millennium Pharm Inc Synthesis of boronic ester and acid compounds
WO2008075376A1 (en) * 2006-12-18 2008-06-26 Natco Pharma Limited Polymorphic forms of bortezomib and process for their preparation
WO2009004350A1 (en) * 2007-07-03 2009-01-08 Pliva Hrvatska D.O.O. Methods for preparing bortezomib and intermediates used in its manufacture
AU2016253697A1 (en) * 2007-08-06 2016-11-24 Millennium Pharmaceuticals, Inc. Proteasome inhibitors
US7442830B1 (en) 2007-08-06 2008-10-28 Millenium Pharmaceuticals, Inc. Proteasome inhibitors
EA034601B1 (ru) * 2007-08-06 2020-02-25 Милленниум Фармасьютикалз, Инк. Способ получения бороновых кислот
JP5261488B2 (ja) * 2007-08-06 2013-08-14 ミレニアム ファーマシューティカルズ， インコーポレイテッド プロテアソーム阻害剤
US20110118274A1 (en) * 2007-08-23 2011-05-19 Cornell Research Foundation, Inc. Proteasome inhibitors and their use in treating pathogen infection and cancer
KR20100051828A (ko) * 2007-09-12 2010-05-18 닥터 레디스 레보러터리즈 리미티드 보르테조밉 및 그의 제조방법
US7838673B2 (en) 2007-10-16 2010-11-23 Millennium Pharmaceuticals, Inc. Proteasome inhibitors
PL2318419T3 (pl) 2008-06-17 2015-08-31 Millennium Pharm Inc Związki estrów boronianowych i ich kompozycje farmaceutyczne
AU2013204896A1 (en) * 2008-09-29 2013-05-16 Millennium Pharmaceuticals, Inc. Derivatives of 1-amino-2-cyclobutylethylboronic acid
AR075090A1 (es) 2008-09-29 2011-03-09 Millennium Pharm Inc Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden.
EP2238973A1 (en) 2009-04-07 2010-10-13 Cephalon France Lyophilized preparations of proteasome inhibitors
CN101899062B (zh) * 2009-05-26 2015-04-15 上海威智医药科技有限公司 α-手性硼酸及硼酸酯的合成工艺
EP2280016A1 (en) 2009-07-27 2011-02-02 LEK Pharmaceuticals d.d. New synthetic route for the preparation of alpha-amino boronic esters via substituted alk-1-ynes
EP2270019A1 (en) 2009-06-19 2011-01-05 LEK Pharmaceuticals d.d. New synthetic route for the preparation of alpha-amino boronic esters
JP2012530116A (ja) 2009-06-19 2012-11-29 レツク・フアーマシユーテイカルズ・デー・デー 脱ハロゲン化なしにハロゲノアルケンを水素化する方法
EP2516449A1 (en) 2009-12-22 2012-10-31 Cephalon, Inc. Proteasome inhibitors and processes for their preparation, purification and use
US20110178287A1 (en) 2010-01-19 2011-07-21 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutic delivery
AU2011214024A1 (en) 2010-02-09 2012-08-30 Ranbaxy Laboratories Limited Process for the preparation of bortezomib
CN101781326B (zh) * 2010-02-11 2013-08-21 福建南方制药股份有限公司 一种制备手性氨基硼酸的中间体及其制备方法
WO2011107912A1 (en) 2010-03-04 2011-09-09 Ranbaxy Laboratories Limited Polymorphic forms of bortezomib
US8263578B2 (en) 2010-03-18 2012-09-11 Innopharma, Inc. Stable bortezomib formulations
KR101530942B1 (ko) * 2010-03-18 2015-06-23 이노파르마, 인코포레이티드 안정한 보르테조밉 포뮬레이션
JP5933523B2 (ja) 2010-03-31 2016-06-08 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． １−アミノ−２−シクロプロピルエチルボロン酸の誘導体
CN101812026B (zh) * 2010-04-12 2013-08-28 亚邦医药股份有限公司 一种硼替佐米的合成方法
CN105797168A (zh) 2010-05-18 2016-07-27 天蓝制药公司 用于治疗自身免疫性疾病或其它疾病的组合物和方法
EP2627636B1 (en) 2010-10-14 2015-09-02 Synthon BV Process for making bortezomib and the intermediates for the process
TW201309303A (zh) 2011-03-03 2013-03-01 Cephalon Inc 用於治療狼瘡的蛋白酶體抑制劑
CN102206188B (zh) * 2011-04-08 2013-02-27 苏州二叶制药有限公司 N-(吡嗪-2-基羰基)-l-苯丙氨酸的制备方法
US8497374B2 (en) 2011-05-12 2013-07-30 Scinopharm Taiwan, Ltd. Process for preparing and purifying bortezomib
CN102268029B (zh) * 2011-05-19 2013-10-09 苏州二叶制药有限公司 化合物（1s,2s,3r,5s）-蒎烷二醇-l-苯丙氨酸-l-亮氨酸硼酸酯的制备
WO2012177835A1 (en) 2011-06-22 2012-12-27 Cephalon, Inc. Proteasome inhibitors and processes for their preparation, purification and use
CN102351890B (zh) * 2011-09-30 2014-07-02 重庆泰濠制药有限公司 一种硼替佐米的合成方法
CN102492021B (zh) * 2011-12-13 2013-10-23 重庆泰濠制药有限公司 硼替佐米的制备工艺
EP2793900B1 (en) * 2011-12-22 2018-08-22 Ares Trading S.A. Alpha-amino boronic acid derivatives, selective immunoproteasome inhibitors
CN103374026A (zh) * 2012-04-27 2013-10-30 重庆医药工业研究院有限责任公司 一种硼替佐米中间体的制备方法
CN103450331B (zh) * 2012-06-05 2016-05-25 山东新时代药业有限公司 一种硼替佐米的精制方法
MX2015003175A (es) * 2012-09-11 2015-07-14 Cipla Ltd Proceso para preparacion de bortezomib.
WO2014072985A1 (en) 2012-11-06 2014-05-15 Natco Pharma Limited Novel boronic acid derivatives as anti cancer agents
EP2919786A4 (en) 2012-11-16 2016-06-01 Shilpa Medicare Ltd PROCESS FOR PREPARING CRYSTALLINE BORTEZOMIB
ES2878118T3 (es) 2012-12-07 2021-11-18 Venatorx Pharmaceuticals Inc Inhibidores de beta-lactamasa
CN103897026A (zh) * 2012-12-29 2014-07-02 朱继东 硼替佐米关键中间体的晶型，制备方法及其运用
CN103897027A (zh) * 2012-12-29 2014-07-02 曹亚英 关键中间体晶型，制备方法及其在硼替佐米合成中的运用
US9403850B2 (en) 2013-01-10 2016-08-02 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
WO2014170628A1 (en) 2013-04-16 2014-10-23 Cipla Limited Process for the preparation of bortezomib mannitol ester
CN104211758B (zh) * 2013-05-29 2020-06-12 深圳翰宇药业股份有限公司 一种硼替佐米的制备方法
CN103497233B (zh) * 2013-09-30 2015-04-08 哈药集团技术中心 一种硼替佐米的制备方法
CN103554219A (zh) * 2013-10-01 2014-02-05 昆明贵研药业有限公司 一种制备硼替佐米的方法
KR101691353B1 (ko) * 2013-12-09 2016-12-30 주식회사 경보제약 보르테조밉의 제조방법 및 그의 신규 중간체
CN111116622A (zh) 2014-02-03 2020-05-08 俄亥俄州创新基金会 硼酸酯和其药物制剂
CN106659761A (zh) 2014-05-20 2017-05-10 千年药物公司 初级癌症疗法后使用的含硼蛋白酶体抑制剂
KR102396753B1 (ko) 2014-06-11 2022-05-12 베나토알엑스 파마슈티컬스, 인크. 베타-락타마제 억제제
JP6420629B2 (ja) * 2014-10-30 2018-11-07 ボーグワーナー インコーポレーテッド チェーンガイドおよびチェーンテンショナアーム
DE102015204151A1 (de) * 2015-03-09 2016-09-15 Adidas Ag Ball, insbesondere Fußball, und Verfahren zur Herstellung eines Balls
JP6223508B2 (ja) * 2016-06-27 2017-11-01 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． プロテアソーム阻害剤
US10889600B2 (en) 2016-08-04 2021-01-12 VenatoRx Pharmaceuticals, Inc. Boron-containing compounds
WO2018150386A1 (en) 2017-02-17 2018-08-23 Fresenius Kabi Oncology Ltd. An improved process for the preparation of boronic acid esters
BR112019018447A2 (pt) 2017-03-06 2020-04-14 Venatorx Pharmaceuticals Inc formas sólidas e composições de combinação compreendendo um inibidor da beta-lactamase e usos das mesmas
WO2018218154A1 (en) 2017-05-26 2018-11-29 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
WO2018218190A1 (en) 2017-05-26 2018-11-29 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
CN109305980B (zh) 2017-07-28 2022-10-11 成都奥璟生物科技有限公司 一种硼酸酯化合物、其合成方法及其用途
WO2019043544A1 (en) * 2017-09-02 2019-03-07 Sun Pharmaceutical Industries Limited PROCESS FOR THE PREPARATION OF IXAZOMIB CITRATE
EP3802551A4 (en) 2018-05-25 2022-03-02 Venatorx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
CN111187336B (zh) * 2018-11-14 2022-05-20 正大天晴药业集团股份有限公司 硼替佐米的精制方法
US11964993B2 (en) 2021-07-03 2024-04-23 Shilpa Pharma Lifesciences Limited Crystalline bortezomib process
US20250059215A1 (en) 2023-08-07 2025-02-20 Tae Life Sciences Llc Trifluoroborate (BF3) Compositions For Use In Boron Neutron Capture Therapy and Methods Thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL31992A (en) * 1968-05-08 1973-07-30 American Cyanamid Co Synthetic thyrocalcitonins and method of making them
ZA794723B (en) * 1978-09-11 1980-08-27 Univ Miami Anti-hypertensive agents
US4525309A (en) 1983-03-15 1985-06-25 Washington State University Research Foundation, Inc. Lewis acid catalysis of the homologation of boronic esters with haloalkylmetal reagents
US4499082A (en) 1983-12-05 1985-02-12 E. I. Du Pont De Nemours And Company α-Aminoboronic acid peptides
US4537773A (en) 1983-12-05 1985-08-27 E. I. Du Pont De Nemours And Company α-Aminoboronic acid derivatives
ES542440A0 (es) * 1985-04-22 1985-12-16 Inke Sa "procedimiento para la obtencion del ester benzilico de 1-(n-(1--etoxicarbonil-3-oxo-fenilpropil)-l-alanil)-l-prolina".
SE8506094D0 (sv) * 1985-12-20 1985-12-20 Astra Laekemedel Ab New antibacterial agents and intermediates therefor
US4701545A (en) 1986-02-12 1987-10-20 Washington State University Research Foundation, Inc. Preparation of α,α-dihaloalkyl boronic esters
US5187157A (en) 1987-06-05 1993-02-16 Du Pont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
US5250720A (en) 1987-06-05 1993-10-05 The Dupont Merck Pharmaceutical Company Intermediates for preparing peptide boronic acid inhibitors of trypsin-like proteases
US5242904A (en) 1987-06-05 1993-09-07 The Dupont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
EP0315574A3 (de) 1987-11-05 1990-08-22 Hoechst Aktiengesellschaft Renin-Inhibitoren
US5106948A (en) 1988-05-27 1992-04-21 Mao Foundation For Medical Education And Research Cytotoxic boronic acid peptide analogs
US6083903A (en) * 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
PT3078667T (pt) * 2001-01-25 2018-12-28 The United States Of America Represented By The Sec Dep Of Health And Human Services Formulação de compostos de ácido borónico
WO2003033507A1 (fr) 2001-10-12 2003-04-24 Kyorin Pharmaceutical Co., Ltd. Derives d'acide benzylmalonique et inhibiteurs de proteasomes les contenant
WO2003033506A1 (fr) * 2001-10-12 2003-04-24 Kyorin Pharmaceutical Co., Ltd. Derive d'acide d'aminoborane et medicament inhibiteur de proteasomes le contenant
SG10201800972PA (en) * 2004-03-30 2018-03-28 Millennium Pharm Inc Synthesis of boronic ester and acid compounds
WO2009004350A1 (en) * 2007-07-03 2009-01-08 Pliva Hrvatska D.O.O. Methods for preparing bortezomib and intermediates used in its manufacture
US7838673B2 (en) * 2007-10-16 2010-11-23 Millennium Pharmaceuticals, Inc. Proteasome inhibitors
JP2012530116A (ja) * 2009-06-19 2012-11-29 レツク・フアーマシユーテイカルズ・デー・デー 脱ハロゲン化なしにハロゲノアルケンを水素化する方法

Also Published As

Publication number Publication date
CA2853272A1 (en) 2005-10-20
CN103396427A (zh) 2013-11-20
ES2457593T3 (es) 2014-04-28
HUE065769T2 (hu) 2024-06-28
HRP20212002T1 (hr) 2022-04-01
PT3385267T (pt) 2021-11-23
ZA200608689B (en) 2007-09-26
IL219853A (en) 2015-05-31
ES2371652T3 (es) 2012-01-05
NZ586824A (en) 2012-03-30
US20190330270A1 (en) 2019-10-31
NO20161350A1 (no) 2006-12-22
EA012927B1 (ru) 2010-02-26
JP2007530687A (ja) 2007-11-01
CN107474062A (zh) 2017-12-15
US9862745B2 (en) 2018-01-09
NO338905B1 (no) 2016-10-31
DOP2011000293A (es) 2011-12-15
CA2560886C (en) 2014-08-12
PT4008721T (pt) 2024-03-21
US20180265546A1 (en) 2018-09-20
CY1112053T1 (el) 2015-11-04
CA2738706A1 (en) 2005-10-20
JP4558039B2 (ja) 2010-10-06
PL1756121T3 (pl) 2012-02-29
ES2974758T3 (es) 2024-07-01
US20100174072A1 (en) 2010-07-08
SI2377869T1 (sl) 2014-05-30
RS62738B1 (sr) 2022-01-31
EA200601795A1 (ru) 2007-04-27
NO343966B1 (no) 2019-07-29
PE20142402A1 (es) 2015-02-04
TW200616646A (en) 2006-06-01
DK1756121T3 (da) 2012-01-09
SG182998A1 (en) 2012-08-30
ES2899606T3 (es) 2022-03-14
PT1756121E (pt) 2011-11-30
NL1028639C2 (nl) 2007-01-17
RS51983B (en) 2012-02-29
US20130005968A1 (en) 2013-01-03
NZ598172A (en) 2013-08-30
IL219853A0 (en) 2012-06-28
HK1246300A1 (zh) 2018-09-07
DK3385267T3 (da) 2021-11-01
NL1033189A1 (nl) 2007-10-22
SG151322A1 (en) 2009-04-30
HK1164320A1 (en) 2012-10-19
CA2560886A1 (en) 2005-10-20
US20050240047A1 (en) 2005-10-27
ME01975B (me) 2015-05-20
US20200157143A1 (en) 2020-05-21
US20150038706A1 (en) 2015-02-05
NO20064893L (no) 2006-12-22
HRP20140339T1 (hr) 2014-05-09
US20210171574A1 (en) 2021-06-10
NO20171939A1 (no) 2006-12-22
IL178250A0 (en) 2006-12-31
WO2005097809A2 (en) 2005-10-20
JP2013100378A (ja) 2013-05-23
FI4008721T3 (fi) 2024-03-19
WO2005097809A3 (en) 2006-02-16
BRPI0509587A (pt) 2007-09-25
ATE521612T1 (de) 2011-09-15
CL2014002252A1 (es) 2014-12-05
HRP20240307T3 (hr) 2024-05-10
HUE056859T2 (hu) 2022-03-28
EP1756121B1 (en) 2011-08-24
IL219856A (en) 2015-05-31
SG182999A1 (en) 2012-08-30
EP3385267A1 (en) 2018-10-10
UY34969A (es) 2015-02-27
DK2377869T3 (da) 2014-04-14
AR097310A2 (es) 2016-03-02
US20200369722A1 (en) 2020-11-26
SI1756121T1 (sl) 2012-03-30
MY145427A (en) 2012-02-15
US20190112334A1 (en) 2019-04-18
HRP20110846T1 (hr) 2011-12-31
ECSP066960A (es) 2006-12-20
UY28830A1 (es) 2005-09-30
SG10201800972PA (en) 2018-03-28
HK1100004A1 (en) 2007-08-31
PL4008721T3 (pl) 2024-05-13
CA2859119A1 (en) 2005-10-20
AR049374A1 (es) 2006-07-26
AU2005230930B2 (en) 2011-09-29
NO344610B1 (no) 2020-02-10
EP4008721B1 (en) 2024-01-03
LT3385267T (lt) 2021-11-10
UA90108C2 (uk) 2010-04-12
NO20191065A1 (no) 2006-12-22
HK1257298A1 (zh) 2019-10-18
CN1960996A (zh) 2007-05-09
PL3385267T3 (pl) 2022-02-14
NL1028639A1 (nl) 2005-10-20
US20160362449A1 (en) 2016-12-15
JP2010241816A (ja) 2010-10-28
JP5414625B2 (ja) 2014-02-12
US20220204558A1 (en) 2022-06-30
EP2377868A1 (en) 2011-10-19
US20210395301A1 (en) 2021-12-23
EP3385267B1 (en) 2021-09-29
CY1115336T1 (el) 2017-01-04
NL1033190C2 (nl) 2007-11-27
CL2010000350A1 (es) 2011-01-28
KR100939598B1 (ko) 2010-02-01
JP2016056180A (ja) 2016-04-21
US10000529B2 (en) 2018-06-19
TWI386212B (zh) 2013-02-21
JP6193960B2 (ja) 2017-09-06
AU2005230930A1 (en) 2005-10-20
SI3385267T1 (sl) 2022-04-29
CN111925385A (zh) 2020-11-13
CN111925385B (zh) 2023-11-21
US20180044377A1 (en) 2018-02-15
RS65253B1 (sr) 2024-03-29
EP2377869B1 (en) 2014-01-29
CN108329337B (zh) 2021-06-25
DK4008721T3 (da) 2024-03-25
EP1756121A2 (en) 2007-02-28
RS53259B (en) 2014-08-29
AR097309A2 (es) 2016-03-02
CN1960996B (zh) 2016-04-20
SI4008721T1 (sl) 2024-05-31
PE20060162A1 (es) 2006-04-07
CR8653A (es) 2007-10-23
IL178250A (en) 2012-06-28
IL219856A0 (en) 2012-06-28
EP2377869A1 (en) 2011-10-19
MX367324B (es) 2019-08-15
CN108329337A (zh) 2018-07-27
CN103396427B (zh) 2018-04-13
JP5894952B2 (ja) 2016-03-30
LT4008721T (lt) 2024-03-25
US7714159B2 (en) 2010-05-11
NZ550522A (en) 2010-08-27
PT2377869E (pt) 2014-04-15
US8283467B2 (en) 2012-10-09
NL1033190A1 (nl) 2007-04-23
CA2738706C (en) 2014-10-14
CY1124753T1 (el) 2022-07-22
EP4008721A1 (en) 2022-06-08
NL1033189C2 (nl) 2008-08-14
SG10201600029PA (en) 2016-02-26
PL2377869T3 (pl) 2014-07-31
KR20070007873A (ko) 2007-01-16
UY35578A (es) 2016-01-08

Similar Documents

Publication Publication Date Title
PE20110075A1 (es) Sintesis de compuestos de ester borico
PE20050158A1 (es) Compuestos inmunosupresores y composiciones
ES2718930T3 (es) Método de preparación de calcobutrol
PE16897A1 (es) Preparacion de triazoles por adicion organometalica a cetonas e intermedios del mismo
NI201100181A (es) Análogos de isoxazol - 3 (2h ) -ona como agentes terapéuticos
PE20071238A1 (es) Proceso para la preparacion de heterociclos hidroxi substituidos
PE20120617A1 (es) Procesos para preparar cobicistat y sus productos intermedios
AR071673A1 (es) Procedimiento para la preparacion de compuestos pirazolicos sustituidos en posiciones 1,3,4
EA201490726A1 (ru) Фармацевтические соединения для применения в терапии инфекции clostridium difficile
PA8785001A1 (es) Compuestos estables en agua, catalizadores y reacciones catalizadas novedosos
ES2706319T3 (es) Un método de preparación de gadobutrol
CU20150051A7 (es) Derivados de n-(piridin-2-il)pirimidin-4-amina que contienen un grupo sulfoximina
PE20110115A1 (es) Cristal de derivados de espirocetal y procedimiento para la preparacion de derivados de espirocetal
AR057909A1 (es) Proceso para preparar montelukast y compuestos relacionados, que utiliza un compuesto intermediario derivado de un ester sulfonico.
PE20120223A1 (es) Compuestos heterociclicos como inhibidores del transportador de glicina-1 (glyt-1)
AR079575A1 (es) Procedimiento para la purificacion de pirazoles
CR9499A (es) Nuevos derivados de fenilpiridinilpiperazina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
PA8563601A1 (es) Acidos-3-(imidazolil)-2- alcoxipropanoicos
PE20060650A1 (es) Metodo para preparar irbesartan e intermediarios del mismo
AR035076A1 (es) Procedimiento y derivados ester utiles para la preparacion de cefalosporinas
RU2012106074A (ru) Новые алкоксиеноны и енаминокетоны и способ их получения
AR045540A1 (es) Metodo de elaboracion de 4,5,6,7 tetrahidroisoxazol [5,4-c] piridin-3-ol (thip)
Johnson et al. Thermorubin 1. structure studies
AR051936A1 (es) Proceso para la preparacion de pirazoles
Liu et al. Synthesis and in vitro antimalarial activity of several simple analogues of peroxyplakoric acid

Legal Events

Date Code Title Description
FG Grant, registration